.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Hepatoprotective regimens during chemotherapy are common in clinical practice. Clinicians often prescribe S-adenosylmethionine (SAMe) to manage liver injury. However, recent research highlights potential risks regarding SAMe breast cancer outcomes. A retrospective cohort study evaluated 1013 women treated for primary breast cancer. Therefore, doctors must balance hepatoprotection with oncologic safety.
The study found that SAMe exposure correlates with shorter overall survival. Moreover, disease-free survival rates were lower in patients receiving SAMe. Using ROC analysis, the team identified a critical threshold for exposure duration. Patients receiving more than four cycles of SAMe faced significant clinical risks. Consequently, high exposure levels more than doubled the hazard for death and disease recurrence.
Why does prolonged exposure impact SAMe breast cancer outcomes negatively? Transcriptomic data suggest that SAMe acts as a universal methyl donor. Increased intratumoral SAMe levels promote specific methylation signals like m6A, m5C, and m7G. Additionally, high METTL3 and METTL14 expression levels may drive tumor progression. These epigenetic changes potentially foster chemoresistance within the tumor microenvironment. Therefore, the biochemical role of SAMe might inadvertently support tumor survival during chemotherapy.
Doctors should reconsider long-term SAMe use for hepatoprotection during chemotherapy. Instead, they might explore alternative regimens that do not interfere with tumor epigenetics. Furthermore, monitoring the duration of supplement use is essential for patient safety. While liver protection remains a priority, maintaining oncologic efficacy is paramount. Further prospective studies will clarify these metabolic interactions in various cancer subtypes.
Prolonged exposure to SAMe, specifically beyond four cycles, is associated with shorter survival and a higher likelihood of cancer recurrence due to epigenetic alterations.
Yes, higher levels of intratumoral SAMe correlate with increased METTL3 and METTL14 expression, which drive RNA methylation pathways linked to poorer prognosis.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study warns that prolonged S-adenosylmethionine (SAMe) use during breast cancer chemotherapy may reduce survival and treatment response....
3 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
